Related Experiment Videos
Bisphosphonates for cancer patients: why, how, and when?
1Department of Medicine, Institut J. Bordet, 1, rue Héger-Bordet, 1000 Bruxelles, Belgium. jj.body@bordet.be
Summary
Bisphosphonates (BPs) effectively treat bone metastases by inhibiting osteoclast activity. Intravenous BPs, like pamidronate, reduce skeletal morbidity and pain in breast cancer and myeloma patients.
Area of Science:
- Oncology
- Pharmacology
- Bone Biology
Background:
- Tumor cells in bone stimulate osteoclast activity, leading to bone resorption and further cancer growth.
- Bisphosphonates (BPs) are standard treatment for cancer hypercalcemia and bone metastases.
- BPs inhibit osteoclast-mediated bone resorption, crucial in managing skeletal complications of cancer.
Purpose of the Study:
- To review the efficacy and application of bisphosphonates in managing bone metastases.
- To discuss optimal dosing, administration routes, and patient selection for BP therapy.
- To explore the role of newer BPs and their potential in adjuvant settings.
Main Methods:
- Review of clinical trials and guidelines regarding bisphosphonate use in bone metastases.
- Analysis of data on pamidronate, clodronate, ibandronate, and zoledronate efficacy.
- Evaluation of bisphosphonates' impact on skeletal morbidity, pain, and response rates.
Main Results:
- Intravenous pamidronate reduces skeletal morbidity by 30-40% and provides pain relief in metastatic bone disease.
- Oral clodronate reduces skeletal events in breast cancer patients with bone metastases.
- Newer bisphosphonates like ibandronate and zoledronate offer improved administration and potential efficacy.
Conclusions:
- Bisphosphonates are essential supportive care for patients with bone metastases, particularly from breast cancer and myeloma.
- Optimal dosing and administration strategies are evolving, with newer agents showing promise.
- Further research is needed to define criteria for stopping BP therapy and explore their use in the adjuvant setting.